Natco is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $10.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Natco's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Descovy | Gilead | Generic | 2031 | FDA-approved 26 Aug 2026 | $2.8B |
| Imbruvica | AbbVie / Johnson & Johnson | Generic | 2032 | Filed with the FDA; court ruled for the brand 2021 | $4.0B |
| Lynparza | AstraZeneca / Merck | Generic | 2027 | Tentatively approved Jul 2026; in litigation | $3.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Natco's share of it.
Natco has FDA approval for Lynparza and Descovy, with no US launch confirmed; and applications filed for Imbruvica. It has is in court over 1 and lost in court over 1. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.